抗dsDNA IgE:预测狼疮肾炎复发的潜在无创检测标志物
WIN-IgE研究为WIN-Lupus试验的辅助研究,纳入52例经活检证实的III或IV±V型活动性狼疮肾炎患者,在随机继续或停用维持免疫抑制治疗时检测血清抗dsDNA IgE和IgG。随访24个月,12例出现活检证实的狼疮肾炎复发;复发者基线抗dsDNA IgE水平更高,抗dsDNA IgE高于1.9任意单位者无复发生存率更低,尤其见于随机停用维持治疗亚组。
要点
- 复发患者基线抗dsDNA IgE水平高于未复发者,抗dsDNA IgG与复发无关。
- 抗dsDNA IgE高于1.9任意单位者无复发生存率更低(p=0.019),停用维持治疗亚组更明显(p=0.002)。
- 全部患者中抗dsDNA IgE高于1.9任意单位对严重狼疮肾炎复发的阳性预测值为0.8。
核心结论
- 结果提示血抗dsDNA IgE可作为狼疮肾炎复发的无创预测标志物。
研究设计与样本
- WIN-IgE为WIN-Lupus研究(NCT01284725)的辅助研究,后者为前瞻性对照临床试验,评估III或IV±V型活动性狼疮肾炎患者经2-3年维持免疫抑制治疗后停用该治疗。
- WIN-IgE纳入所有在随机继续或停用维持免疫抑制治疗时留有可用血清的患者,共52例,继续组25例、停药组27例。
- 采用ELISA定量血清抗dsDNA抗体IgE和IgG,比较随访24个月内复发与未复发患者间的差异。
主要发现
- 52例患者中12例出现活检证实的狼疮肾炎复发。
- 复发患者基线抗dsDNA IgE水平高于未复发者。
- 抗dsDNA IgG与复发无关联。
- 抗dsDNA IgE高于1.9任意单位者无复发生存率低于低于该阈值者(p=0.019),在随机停用维持治疗亚组中更明显(p=0.002)。
- 全部患者中抗dsDNA IgE高于1.9任意单位对严重狼疮肾炎复发的阳性预测值为0.8。
关键数值与推荐
- 抗dsDNA IgE阈值1.9任意单位:高于该阈值者无复发生存率更低(p=0.019),停用维持治疗亚组p=0.002。
- 全部患者中抗dsDNA IgE高于1.9任意单位对严重狼疮肾炎复发的阳性预测值为0.8。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Discontinuation or continuation of maintenance immunosuppressive therapy (MIST) after a severe lupus nephritis (LN) requires measuring the risk of relapse but reliable clinical and biological markers are lacking. The WIN-IgE study assesses the value of serum anti-dsDNA IgE autoantibodies as a biomarker for the prediction of relapse in severe LN. METHODS: WIN-IgE is an ancillary study of the WIN-Lupus study (NCT01284725), a prospective controlled clinical trial which evaluated the discontinuation of MIST after 2-3 years in class III or IV±V LN with active lesions. WIN-IgE included all patients with available serum collected at randomisation for continuation or discontinuation of MIST. In these sera, anti-dsDNA antibodies, IgE and IgG, were quantified by ELISA and compared between patients who experienced LN relapse and those who did not during the 24 months of follow-up. RESULTS: 52 patients were included, 25 in the MIST continuation group and 27 in the MIST discontinuation group, 12 experienced a biopsy-proven relapse of LN. Initial anti-dsDNA IgE antibodies levels were higher in patients with subsequent LN relapse. Anti-dsDNA IgG was not associated with relapse. Survival without LN relapse was lower in patients with anti-dsDNA IgE levels above vs below a threshold of 1.9 arbitrary units (p=0.019), particularly in the subgroup of patients randomised to discontinue MIST (p=0.002). In all patients, anti-dsDNA IgE above 1.9 arbitrary units had a positive predictive value of 0.8 for severe LN relapse. CONCLUSIONS: These results suggest blood anti-dsDNA IgE as a non-invasive predictive marker of LN relapse.
引用
- Himbert M, Jourde-Chiche N, Chapart L, et al. Anti-dsDNA IgE: a potential non-invasive test for prediction of lupus nephritis relapse. RMD Open. 2024. PMID: 38942591. doi:10.1136/rmdopen-2024-004255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。